WorthlessViews

WorthlessViews

Bausch + Lomb NYSE:BLCO , a strong name in the eye health world, is trading within my historical simple moving average area and appears to be gaining upward momentum. I usually do not like to enter companies this earlier (more data is always better), but this company has very strong earnings and a solid track record. Earnings are forecasted to grow 57% per year...

WorthlessViews Updated 

Sabre Corporation's NASDAQ:SABR earnings have slowly been improving since the pandemic and may be heading into profitability by 2025/2026. Disinterest in the stock may also be waning as the price creeps closer to my selected historical simple moving average (SMA, white and teal lines). Often, but not always, as the price nears this line, it jumps to make contact...

WorthlessViews Updated 

StoneCo NASDAQ:STNE revenue rise is staggering. Position started at $8.76. Chart looks ready for a move up, but nothing is guaranteed. Price Targets into 2027: $10.00 $12.00 $14.00 $16.00 $30.00 (long-term view)

WorthlessViews Updated 

Alibaba Group NYSE:BABA has the potential for massive growth. From a technical analysis perspective (and using my selected simply moving averages (SMAs)), the price of NYSE:BABA is reconnecting with its primary SMA. It could ride this area for a while as it consolidates further, but this often means a future reversal of the downward trend. Thus, at $80.00, ...

WorthlessViews

Zoetis NYSE:ZTS , the largest global animal health company, generated more than $9 billion in revenue in 2024 and earnings have grown 9.3% per year over the past 5 years. Free cash flow for FY2024 was over $2.2 billion. Dividend consistently raised every year for the past for years (currently 1.28%). The growth of the company isn't expected to slow any time soon,...

WorthlessViews Updated 

Johnson & Johnson NYSE:JNJ is strong (but highly controversial) company with anticipated earnings growth on the horizon. With a P/E of 23x, steady dividend growth record, low debt, and expected increased cashflow, the future is optimistic for NYSE:JNJ if they can stay out of the shady spotlight... While the historical simple moving average I've selected...

WorthlessViews

Redfin $NASDAQ:RDFN. Yes, housing is starting to finally slide as mortgage rates remain high, housing inventory increases, and pending sales drop. I can see an argument to wait to enter NASDAQ:RDFN and I can't truly argue against it for 2025 (a dip is possible into the $4's if things really take a bad turn). But what I like about Redfin is they do not invest in...

WorthlessViews

GoodRX NASDAQ:GDRX . Going long at $5.00. Pros: Revenue is growing and is expected to reach almost $1 billion by 2027 Debt-to-equity = 0.71x (low) Monthly active users continue to increase (+7% during Q3 of 2024) From a technical analysis perspective, the downward trend is starting to reverse, and the price has connected with my historical simple...

WorthlessViews Updated 

Warren Buffett goes for Dominos ( NASDAQ:DPZ ), but I'm here for Pappa Johns $NASDAQ:PZZA. Pros: Earnings are forecast to grow 10.92% per year Revenue grew from $1.8 billion in 2020 to $2.1 billion through Q3 of 2024 - expected to continue to rise through 2027 Free cash flow expected to improve 5.1% dividend A lot of options awarded to insiders in...

WorthlessViews

Under Armour $NYSE:UA. Price may break my historical simple moving average area/lines and dip into the low $6s, but the convergence of price with these lines often means a future price increase. Fundamentally, the stock continues to surprise with earnings beat after earnings beat. While economic headwinds are likely ahead in the retail market, global exposure may...

WorthlessViews

Figs Inc $NYSE:FIGS. Technical analysis play first, fundamentals second. My selected historical simple moving average lines have converged with the stock price, which often leads to sideways trading and a reversal in the downward trend (i.e. future price increase). The downward trend is flattening, but that doesn't mean post-earnings drop to $1.50-$2.00 isn't...

WorthlessViews

Reentering Estee Lauder at $67.33 due to the persistence of the Director, Paul Fribourg, buying around $33,000,000 worth of shares between $63-$66 (even after the earnings debacle). While the company had a horrendous outlook for FY2025, the bad news may be already priced in (i.e. cutting 7,000 jobs, weak sales, etc.). A "profit recovery and growth plan" is...

WorthlessViews Updated 

Teladoc Health NYSE:TDOC - Initial position started at $9.91 with the potential for the price gap in the $7's to be closed in the near future (likely another entry there unless fundamentals change) Pros: User base of over 90 million and growing Revenue grew from $555 million in 2019 to $2.6 billion through Q3 of 2024 Positive free cash flow since...

WorthlessViews Updated 

Not much to write about here except the stock has reentered the "crash" simple moving average area (see green lines). Often, this signals an overall bottom, but it doesn't mean a further dip below $40 isn't possible in the near-term. Personally, I can't ignore this reentry and thus have started a position at $43 (after closing out a previous position in October in...

WorthlessViews Updated 

Similar to my analysis of Paramount Global NASDAQ:PARA ( www.tradingview.com ), the chart for Lions Gate NYSE:LGF.A looks very interesting as the price reenters my selected historical simple moving average (SMA). Typically, this means a near-term upward trend in price is imminent or even a complete breakout through the historical SMA (but not guaranteed)....

WorthlessViews

Pros: Earnings are forecast to grow 13.29% per year Earnings grew by 18.4% over the past year 2.3% dividend yield Cons: Insider selling and exercising of options Debt-to-equity ratio of 3.8x Small price gap on the daily chart near $41 that may close prior to a move up. If people can't buy houses, they will travel... thus, at $43.76, Las...

WorthlessViews Updated 

As one of the largest pharmaceutical companies in the world, Novartis NYSE:NVS is poised to grow well into 2027. It's trading at a 17x P/E, earnings are forecast to grow 7% per year, it has low debt, and has been raising its dividend over the past few years (3.8%). The price on the daily chart is nearing the historical simple moving average line and may be...

WorthlessViews

The Good: NYSE:NVO expects its GLP-1 drugs Wegovy and Ozempic to soon come off the Food and Drug Administration's official shortage list. Just reported better-than-expected net profit in Q4 2024, amid soaring demand for its obesity drugs. Revenues for the Q4 2024 came in at $11.6 billion, up 30% compared to the same quarter in 2023. From a technical...